One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.
Cramer JP1, Jelinek T2, Paulke-Korinek M3, Reisinger EC4, Dieckmann S5, Alberer M6, Bühler S7, Bosse D8, Meyer S8, Fragapane E9, Costantini M9,Pellegrini M10, Lattanzi M9, Dovali C9.
Serological response following re-vaccination with Salmonella typhi Vi-capsular polysaccharide vaccines in healthy adult travellers.
Roggelin L1, Vinnemeier CD2, Fischer-Herr J3, Johnson-Weaver BT4, Rolling T5, Burchard GD6, Staats HF7, Cramer JP8.
A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
Roggelin L1,2, Vinnemeier CD1,2, Meyer S3, Witte K3, Marx L2,4, Theeß W2, Burchard GD1,2, Rolling T1,2, Cramer JP1,2.
Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine.
Jelinek T1, Cramer JP2, Dieckmann S3, Hatz C4, Paulke-Korinek M5, Alberer M6, Reisinger EC7, Costantini M8, Gniel D9, Bosse D9, Lattanzi M10.
Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala.
Behrens RH1, Cramer JP2, Jelinek T3, Shaw H4, von Sonnenburg F5, Wilbraham D6, Weinke T7, Bell DJ8, Asturias E9, Pauwells HL10, Maxwell R11, Paredes-Paredes M12, Glenn GM13, Dewasthaly S14, Stablein DM15, Jiang ZD16, DuPont HL17.
Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
Vinnemeier CD1, Fischer-Herr J1, Meyer S2, Liebig K2, Theeß W3, Burchard GD1, Cramer JP1.
Efficacy of a travelers' diarrhea vaccine system in travelers to India.
Steffen R1, Cramer JP, Burchard G, Jelinek T, Schwarz U, Ramdas P, Chatterjee S, Jiang ZD, DuPont HL, Dewasthaly S, Westritschnig K, Behrens RH.
Clinical relevance of different biomarkers in imported plasmodium falciparum malaria in adults: a case control study.
Stauga S1, Hahn A, Brattig NW, Fischer-Herr J, Baldus S, Burchard GD, Cramer JP.
A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.
Hatz C1, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, Lattanzi M, Hilbert AK, Cioppa GD, Leroux-Roels G.
Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany.
Cramer J1, Mac T, Hogan B, Stauga S, Eberhardt S, Wichmann O, Mertens T, Burchard G.
Reduced cardiac output in imported Plasmodium falciparum malaria.
Herr J1, Mehrfar P, Schmiedel S, Wichmann D, Brattig NW, Burchard GD, Cramer JP.
Short-Term Immunogenicity and Safety of an Accelerated Pre-Exposure Prophylaxis Regimen With Japanese Encephalitis Vaccine in Combination With a Rabies Vaccine: A Phase III, Multicenter, Observer-Blind Study.
Jelinek T1, Burchard GD2, Dieckmann S3, Bühler S4, Paulke-Korinek M5, Nothdurft HD6, Reisinger E7, Ahmed K8, Bosse D9, Meyer S9, Costantini M10,Pellegrini M10.